Skip to main content
Top
Published in: Current Colorectal Cancer Reports 6/2017

01-12-2017 | Diagnostic and Interventional Radiology Innovations in Colorectal Cancer (G de Prisco, Section Editor)

Liver Imaging for Colorectal Cancer Metastases

Authors: Daniel R. Ludwig, Aaron J. Mintz, Vanessa R. Sanders, Kathryn J. Fowler

Published in: Current Colorectal Cancer Reports | Issue 6/2017

Login to get access

Abstract

Purpose of Review

The prognosis of colorectal carcinoma with liver metastases (CRLM) is driven largely by the resectability of hepatic metastatic disease. An increasing number of systemic and hepatic-directed therapies are being applied in the neoadjuvant setting to downstage patients for surgical eligibility. The goal of this review is to describe the use of imaging techniques in the management of CRLM with an emphasis on staging, pretreatment planning, and response assessment.

Recent Findings

While CT has an established role in screening for hepatic metastatic disease, MRI with hepatobiliary contrast has emerged as the workhorse technique in patients with CRLM in whom surgical intervention is being considered. Multiphasic CT and/or contrast-enhanced ultrasound are useful adjunctive tools, particularly when MRI is contraindicated. PET/CT provides added value in candidates for surgical resection or hepatic-directed therapy, primarily in its ability to exclude extra-hepatic metastatic disease.

Summary

Accurate staging and detailed presurgical anatomic assessment including volumetry, guide management in patients with CRLM, particularly in selecting for resection and hepatic-directed therapies.
Literature
1.
2.
go back to reference Siegel RL, et al. Colorectal cancer incidence patterns in the United States, 1974–2013. J Natl Cancer Inst. 2017;109(8). Siegel RL, et al. Colorectal cancer incidence patterns in the United States, 1974–2013. J Natl Cancer Inst. 2017;109(8).
3.
go back to reference van der Geest LG, et al. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015;32(5):457–65.PubMedCrossRef van der Geest LG, et al. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015;32(5):457–65.PubMedCrossRef
5.
go back to reference • Tsang ME, et al. FC Wright, et al. editors. Colorectal Liver Metastases, in Surgical Oncology Manual. Cham: Springer International Publishing; 2016. p. 101–113. Summarizes treatment paradigms for CRLM, with a focus on resection strategies, systemic treatment, and ablative options. • Tsang ME, et al. FC Wright, et al. editors. Colorectal Liver Metastases, in Surgical Oncology Manual. Cham: Springer International Publishing; 2016. p. 101–113. Summarizes treatment paradigms for CRLM, with a focus on resection strategies, systemic treatment, and ablative options.
6.
go back to reference Van Cutsem E, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42(14):2212–21.PubMedCrossRef Van Cutsem E, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42(14):2212–21.PubMedCrossRef
7.
go back to reference Kinkel K, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002;224(3):748–56.PubMedCrossRef Kinkel K, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002;224(3):748–56.PubMedCrossRef
9.
go back to reference Cantisani V, et al. Liver metastases: contrast-enhanced ultrasound compared with computed tomography and magnetic resonance. World J Gastroenterol: WJG. 2014;20(29):9998.PubMedPubMedCentralCrossRef Cantisani V, et al. Liver metastases: contrast-enhanced ultrasound compared with computed tomography and magnetic resonance. World J Gastroenterol: WJG. 2014;20(29):9998.PubMedPubMedCentralCrossRef
10.
go back to reference von Herbay A, et al. Real-time imaging with the sonographic contrast agent SonoVue. J Ultrasound Med. 2004;23(12):1557–68.CrossRef von Herbay A, et al. Real-time imaging with the sonographic contrast agent SonoVue. J Ultrasound Med. 2004;23(12):1557–68.CrossRef
11.
go back to reference Bernatik T, et al. Detection of liver metastases: comparison of contrast-enhanced wide-band harmonic imaging with conventional ultrasonography. J Ultrasound Med. 2001;20(5):509–15.PubMedCrossRef Bernatik T, et al. Detection of liver metastases: comparison of contrast-enhanced wide-band harmonic imaging with conventional ultrasonography. J Ultrasound Med. 2001;20(5):509–15.PubMedCrossRef
12.
go back to reference Vialle R, et al. Preoperative detection of hepatic metastases from colorectal cancer: prospective comparison of contrast-enhanced ultrasound and multidetector-row computed tomography (MDCT). Diagn Interv Imaging. 2016;97(9):851–5.PubMedCrossRef Vialle R, et al. Preoperative detection of hepatic metastases from colorectal cancer: prospective comparison of contrast-enhanced ultrasound and multidetector-row computed tomography (MDCT). Diagn Interv Imaging. 2016;97(9):851–5.PubMedCrossRef
13.
go back to reference Cabassa P, et al. Liver metastases: sulphur hexafluoride–enhanced ultrasonography for lesion detection: a systematic review. Ultrasound Med Biol. 2010;36(10):1561–7.PubMedCrossRef Cabassa P, et al. Liver metastases: sulphur hexafluoride–enhanced ultrasonography for lesion detection: a systematic review. Ultrasound Med Biol. 2010;36(10):1561–7.PubMedCrossRef
14.
go back to reference Network NCC. Clinical practice guidelines in oncology (NCCN guidelines): colon cancer. Version 2.2016. November 24, 2015. 2015. Network NCC. Clinical practice guidelines in oncology (NCCN guidelines): colon cancer. Version 2.2016. November 24, 2015. 2015.
15.
go back to reference •• Fowler KJ, et al. ACR appropriateness criteria® pretreatment staging of colorectal cancer. J Am Coll Radiol. 2017;14(5):S234–44. Provides consensus imaging recommendations from the ACR on pretreatment staging of colorectal cancer.PubMedCrossRef •• Fowler KJ, et al. ACR appropriateness criteria® pretreatment staging of colorectal cancer. J Am Coll Radiol. 2017;14(5):S234–44. Provides consensus imaging recommendations from the ACR on pretreatment staging of colorectal cancer.PubMedCrossRef
16.
go back to reference Sahani DV, et al. Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma. Ann Surg. 2014;259(5):861–72.PubMedCrossRef Sahani DV, et al. Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma. Ann Surg. 2014;259(5):861–72.PubMedCrossRef
17.
go back to reference Lordan JT, Stenson KM, Karanjia ND. The value of intraoperative ultrasound and preoperative imaging, individually and in combination, in liver resection for metastatic colorectal cancer. Ann R Coll Surg Engl. 2011;93(3):246–9.PubMedPubMedCentralCrossRef Lordan JT, Stenson KM, Karanjia ND. The value of intraoperative ultrasound and preoperative imaging, individually and in combination, in liver resection for metastatic colorectal cancer. Ann R Coll Surg Engl. 2011;93(3):246–9.PubMedPubMedCentralCrossRef
18.
go back to reference Kartalis N, et al. The added value of contrast-enhanced ultrasound in patients with colorectal cancer undergoing preoperative evaluation with extensive gadobenate dimeglumine liver MRI. Eur Radiol. 2011;21(10):2067–73.PubMedCrossRef Kartalis N, et al. The added value of contrast-enhanced ultrasound in patients with colorectal cancer undergoing preoperative evaluation with extensive gadobenate dimeglumine liver MRI. Eur Radiol. 2011;21(10):2067–73.PubMedCrossRef
19.
go back to reference Wagnetz U, et al. Intraoperative ultrasound of the liver in primary and secondary hepatic malignancies: comparison with preoperative 1.5-T MRI and 64-MDCT. Am J Roentgenol. 2011;196(3):562–8.CrossRef Wagnetz U, et al. Intraoperative ultrasound of the liver in primary and secondary hepatic malignancies: comparison with preoperative 1.5-T MRI and 64-MDCT. Am J Roentgenol. 2011;196(3):562–8.CrossRef
20.
go back to reference Arita J, et al. Routine preoperative liver-specific magnetic resonance imaging does not exclude the necessity of contrast-enhanced intraoperative ultrasound in hepatic resection for colorectal liver metastasis. Ann Surg. 2015;262(6):1086–91.PubMedCrossRef Arita J, et al. Routine preoperative liver-specific magnetic resonance imaging does not exclude the necessity of contrast-enhanced intraoperative ultrasound in hepatic resection for colorectal liver metastasis. Ann Surg. 2015;262(6):1086–91.PubMedCrossRef
21.
go back to reference Ellebæk SB, et al. Intraoperative ultrasound as a screening modality for the detection of liver metastases during resection of primary colorectal cancer-a systematic review. Ultrasound Int Open. 2017;3(02):E60–8.PubMedPubMedCentralCrossRef Ellebæk SB, et al. Intraoperative ultrasound as a screening modality for the detection of liver metastases during resection of primary colorectal cancer-a systematic review. Ultrasound Int Open. 2017;3(02):E60–8.PubMedPubMedCentralCrossRef
22.
go back to reference Fowler KJ, Linehan DC, Menias CO. Colorectal liver metastases: state of the art imaging. Ann Surg Oncol. 2013;20(4):1185–93.PubMedCrossRef Fowler KJ, Linehan DC, Menias CO. Colorectal liver metastases: state of the art imaging. Ann Surg Oncol. 2013;20(4):1185–93.PubMedCrossRef
23.
go back to reference Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010;257(3):674–84.PubMedCrossRef Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010;257(3):674–84.PubMedCrossRef
24.
go back to reference van Kessel CS, et al. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol. 2012;19(9):2805–13.PubMedPubMedCentralCrossRef van Kessel CS, et al. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol. 2012;19(9):2805–13.PubMedPubMedCentralCrossRef
25.
go back to reference Muhi A, et al. Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI. J Magn Reson Imaging. 2011;34(2):326–35.PubMedCrossRef Muhi A, et al. Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI. J Magn Reson Imaging. 2011;34(2):326–35.PubMedCrossRef
26.
go back to reference Kim Y, et al. Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT. Br J Radiol. 2012;85(1013):539–47.PubMedPubMedCentralCrossRef Kim Y, et al. Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT. Br J Radiol. 2012;85(1013):539–47.PubMedPubMedCentralCrossRef
27.
go back to reference Ch'en IY, et al. Do arterial phase helical CT images improve detection or characterization of colorectal liver metastases? J Comput Assist Tomogr. 1997;21(3):391–7.PubMedCrossRef Ch'en IY, et al. Do arterial phase helical CT images improve detection or characterization of colorectal liver metastases? J Comput Assist Tomogr. 1997;21(3):391–7.PubMedCrossRef
28.
go back to reference Meijerink MR, et al. Subtraction-multiphase-CT unbeneficial for early detection of colorectal liver metastases. Eur J Radiol. 2010;74(3):e132–7.PubMedCrossRef Meijerink MR, et al. Subtraction-multiphase-CT unbeneficial for early detection of colorectal liver metastases. Eur J Radiol. 2010;74(3):e132–7.PubMedCrossRef
29.
go back to reference Wicherts DA, et al. Incremental value of arterial and equilibrium phase compared to hepatic venous phase CT in the preoperative staging of colorectal liver metastases: an evaluation with different reference standards. Eur J Radiol. 2011;77(2):305–11.PubMedCrossRef Wicherts DA, et al. Incremental value of arterial and equilibrium phase compared to hepatic venous phase CT in the preoperative staging of colorectal liver metastases: an evaluation with different reference standards. Eur J Radiol. 2011;77(2):305–11.PubMedCrossRef
30.
go back to reference Kulemann V, et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol. 2011;79(2):e1–6.PubMedCrossRef Kulemann V, et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol. 2011;79(2):e1–6.PubMedCrossRef
31.
go back to reference Van Kessel C, et al. Accuracy of multislice liver CT and MRI for preoperative assessment of colorectal liver metastases after neoadjuvant chemotherapy. Dig Surg. 2011;28(1):36–43.PubMedCrossRef Van Kessel C, et al. Accuracy of multislice liver CT and MRI for preoperative assessment of colorectal liver metastases after neoadjuvant chemotherapy. Dig Surg. 2011;28(1):36–43.PubMedCrossRef
32.
go back to reference •• Schulz A, et al. Diagnostic performance of CT, MRI and PET/CT in patients with suspected colorectal liver metastases: the superiority of MRI. Acta Radiol. 2016;57(9):1040–8. Recent study demonstrating a higher sensitivity of hepatobiliary phase MRI compared to CT and PET/CT for the detection of CRLM, in particular for lesions smaller than 1 cm.PubMedCrossRef •• Schulz A, et al. Diagnostic performance of CT, MRI and PET/CT in patients with suspected colorectal liver metastases: the superiority of MRI. Acta Radiol. 2016;57(9):1040–8. Recent study demonstrating a higher sensitivity of hepatobiliary phase MRI compared to CT and PET/CT for the detection of CRLM, in particular for lesions smaller than 1 cm.PubMedCrossRef
33.
go back to reference Vilgrain V, et al. A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases. Eur Radiol. 2016;26(12):4595–615.PubMedCrossRef Vilgrain V, et al. A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases. Eur Radiol. 2016;26(12):4595–615.PubMedCrossRef
34.
go back to reference Eiber M, et al. Detection and classification of focal liver lesions in patients with colorectal cancer: retrospective comparison of diffusion-weighted MR imaging and multi-slice CT. Eur J Radiol. 2012;81(4):683–91.PubMedCrossRef Eiber M, et al. Detection and classification of focal liver lesions in patients with colorectal cancer: retrospective comparison of diffusion-weighted MR imaging and multi-slice CT. Eur J Radiol. 2012;81(4):683–91.PubMedCrossRef
35.
go back to reference Macera A, et al. Staging of colorectal liver metastases after preoperative chemotherapy. Diffusion-weighted imaging in combination with Gd-EOB-DTPA MRI sequences increases sensitivity and diagnostic accuracy. Eur Radiol. 2013;23(3):739–47.PubMedCrossRef Macera A, et al. Staging of colorectal liver metastases after preoperative chemotherapy. Diffusion-weighted imaging in combination with Gd-EOB-DTPA MRI sequences increases sensitivity and diagnostic accuracy. Eur Radiol. 2013;23(3):739–47.PubMedCrossRef
36.
go back to reference Kenis C, et al. Diagnosis of liver metastases: can diffusion-weighted imaging (DWI) be used as a stand alone sequence? Eur J Radiol. 2012;81(5):1016–23.PubMedCrossRef Kenis C, et al. Diagnosis of liver metastases: can diffusion-weighted imaging (DWI) be used as a stand alone sequence? Eur J Radiol. 2012;81(5):1016–23.PubMedCrossRef
37.
go back to reference Yokoo T, et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology. 2009;251(1):67–76.PubMedPubMedCentralCrossRef Yokoo T, et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology. 2009;251(1):67–76.PubMedPubMedCentralCrossRef
38.
go back to reference Doo KW, et al. “Pseudo washout” sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. Am J Roentgenol. 2009;193(6):W490–6.CrossRef Doo KW, et al. “Pseudo washout” sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. Am J Roentgenol. 2009;193(6):W490–6.CrossRef
39.
40.
go back to reference Fraum TJ, et al. Gadolinium-based contrast agents: a comprehensive risk assessment. J Magn Reson Imaging. 2017. Fraum TJ, et al. Gadolinium-based contrast agents: a comprehensive risk assessment. J Magn Reson Imaging. 2017.
41.
go back to reference Ramos E, et al. Preoperative staging of patients with liver metastases of colorectal carcinoma. Does PET/CT really add something to multidetector CT? Ann Surg Oncol. 2011;18(9):2654.PubMedCrossRef Ramos E, et al. Preoperative staging of patients with liver metastases of colorectal carcinoma. Does PET/CT really add something to multidetector CT? Ann Surg Oncol. 2011;18(9):2654.PubMedCrossRef
42.
go back to reference Fernandez FG, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240(3):438.PubMedPubMedCentralCrossRef Fernandez FG, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240(3):438.PubMedPubMedCentralCrossRef
43.
go back to reference Briggs R, et al. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer. Clin Radiol. 2011;66(12):1167–74.PubMedCrossRef Briggs R, et al. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer. Clin Radiol. 2011;66(12):1167–74.PubMedCrossRef
44.
go back to reference Llamas-Elvira JM, et al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging. 2007;34(6):859–67.PubMedCrossRef Llamas-Elvira JM, et al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging. 2007;34(6):859–67.PubMedCrossRef
45.
go back to reference Chan K, et al. Evidence-based guideline recommendations on the use of positron emission tomography imaging in colorectal cancer. Clin Oncol. 2012;24(4):232–49.CrossRef Chan K, et al. Evidence-based guideline recommendations on the use of positron emission tomography imaging in colorectal cancer. Clin Oncol. 2012;24(4):232–49.CrossRef
47.
go back to reference Yong T, et al. Sensitivity of PET/MR images in liver metastases from colorectal carcinoma. Hell J Nucl Med. 2011;14(3):264–8.PubMed Yong T, et al. Sensitivity of PET/MR images in liver metastases from colorectal carcinoma. Hell J Nucl Med. 2011;14(3):264–8.PubMed
48.
go back to reference Jones R, et al. Controversies in the oncosurgical management of liver limited stage IV colorectal cancer. Surg Oncol. 2014;23(2):53–60.PubMedCrossRef Jones R, et al. Controversies in the oncosurgical management of liver limited stage IV colorectal cancer. Surg Oncol. 2014;23(2):53–60.PubMedCrossRef
49.
go back to reference Simmonds P, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94(7):982–99.PubMedPubMedCentralCrossRef Simmonds P, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94(7):982–99.PubMedPubMedCentralCrossRef
50.
go back to reference Alberts SR, Poston GJ. Treatment advances in liver-limited metastatic colorectal cancer. Clin Colorectal Cancer. 2011;10(4):258–65.PubMedCrossRef Alberts SR, Poston GJ. Treatment advances in liver-limited metastatic colorectal cancer. Clin Colorectal Cancer. 2011;10(4):258–65.PubMedCrossRef
51.
go back to reference Ome Y, et al. Two-stage hepatectomy and associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) in treating liver metastases of rectal cancer: a case report. SpringerPlus. 2015;4(1):194.PubMedPubMedCentralCrossRef Ome Y, et al. Two-stage hepatectomy and associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) in treating liver metastases of rectal cancer: a case report. SpringerPlus. 2015;4(1):194.PubMedPubMedCentralCrossRef
52.
53.
go back to reference Maundura M and Koea JB. Assessment and optimization of the future liver remnant, in Updates in Liver Cancer. InTech; 2017. Maundura M and Koea JB. Assessment and optimization of the future liver remnant, in Updates in Liver Cancer. InTech; 2017.
54.
go back to reference Aloia T, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24(31):4983–90.PubMedCrossRef Aloia T, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24(31):4983–90.PubMedCrossRef
55.
go back to reference Shindoh J, et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol. 2013;20(8):2493–500.PubMedCrossRef Shindoh J, et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol. 2013;20(8):2493–500.PubMedCrossRef
56.
go back to reference Gomez D, et al. Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis. Br J Surg. 2007;94(11):1395–402.PubMedCrossRef Gomez D, et al. Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis. Br J Surg. 2007;94(11):1395–402.PubMedCrossRef
57.
go back to reference Orcutt ST, et al. Portal vein embolization as an oncosurgical strategy prior to major hepatic resection: anatomic, surgical, and technical considerations. Front Surg. 2016;3. Orcutt ST, et al. Portal vein embolization as an oncosurgical strategy prior to major hepatic resection: anatomic, surgical, and technical considerations. Front Surg. 2016;3.
58.
go back to reference Ribero D, Chun YS, and Vauthey J-N. Standardized liver volumetry for portal vein embolization. in Seminars in interventional radiology. 2008. © Thieme Medical Publishers. Ribero D, Chun YS, and Vauthey J-N. Standardized liver volumetry for portal vein embolization. in Seminars in interventional radiology. 2008. © Thieme Medical Publishers.
59.
go back to reference Karanicolas PJ, et al. Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases. JAMA Surg. 2013;148(7):597–601.PubMedPubMedCentralCrossRef Karanicolas PJ, et al. Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases. JAMA Surg. 2013;148(7):597–601.PubMedPubMedCentralCrossRef
60.
go back to reference Evrard S, et al. Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. PLoS One. 2014;9(12):e114404.PubMedPubMedCentralCrossRef Evrard S, et al. Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. PLoS One. 2014;9(12):e114404.PubMedPubMedCentralCrossRef
61.
go back to reference D’Angelica MI, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261(2):353.PubMedPubMedCentralCrossRef D’Angelica MI, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261(2):353.PubMedPubMedCentralCrossRef
62.
go back to reference Ault GT and Cologne KG. Colorectal cancer: management of stage IV disease, in The ASCRS Textbook of Colon and Rectal Surgery. Springer; 2016. p. 589–616. Ault GT and Cologne KG. Colorectal cancer: management of stage IV disease, in The ASCRS Textbook of Colon and Rectal Surgery. Springer; 2016. p. 589–616.
63.
go back to reference Tanaka K, Ichikawa Y, Endo I. Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review. Int J Clin Oncol. 2011;16(5):452.PubMedCrossRef Tanaka K, Ichikawa Y, Endo I. Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review. Int J Clin Oncol. 2011;16(5):452.PubMedCrossRef
64.
go back to reference Khan K, et al. Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone? World J Gastroenterol: WJG. 2014;20(35):12391.PubMedPubMedCentralCrossRef Khan K, et al. Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone? World J Gastroenterol: WJG. 2014;20(35):12391.PubMedPubMedCentralCrossRef
65.
go back to reference Tomasello G, et al. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;e170278-e170278. Tomasello G, et al. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;e170278-e170278.
66.
go back to reference Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–16.PubMedCrossRef Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–16.PubMedCrossRef
67.
go back to reference Trillet-Lenoir V, et al. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol. 2002;75(899):903–8.PubMedCrossRef Trillet-Lenoir V, et al. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol. 2002;75(899):903–8.PubMedCrossRef
68.
go back to reference Chun YS, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302(21):2338–44.PubMedPubMedCentralCrossRef Chun YS, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302(21):2338–44.PubMedPubMedCentralCrossRef
69.
go back to reference McDermott S and Gervais DA. Radiofrequency ablation of liver tumors. in Seminars in interventional radiology. Thieme Medical Publishers; 2013. McDermott S and Gervais DA. Radiofrequency ablation of liver tumors. in Seminars in interventional radiology. Thieme Medical Publishers; 2013.
70.
go back to reference McLoney ED, Isaacson AJ, and Keating P. The role of PET imaging before, during, and after percutaneous hepatic and pulmonary tumor ablation. in Seminars in interventional radiology. Thieme Medical Publishers; 2014. McLoney ED, Isaacson AJ, and Keating P. The role of PET imaging before, during, and after percutaneous hepatic and pulmonary tumor ablation. in Seminars in interventional radiology. Thieme Medical Publishers; 2014.
71.
go back to reference Barker DW, et al. Evaluation of liver metastases after radiofrequency ablation: utility of 18F-FDG PET and PET/CT. Am J Roentgenol. 2005;184(4):1096–102.CrossRef Barker DW, et al. Evaluation of liver metastases after radiofrequency ablation: utility of 18F-FDG PET and PET/CT. Am J Roentgenol. 2005;184(4):1096–102.CrossRef
72.
go back to reference Livraghi T, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226(2):441–51.PubMedCrossRef Livraghi T, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226(2):441–51.PubMedCrossRef
73.
go back to reference Kuhlmann K, et al. Management of disappearing colorectal liver metastases. Eur J Surg Oncol. 2016;42(12):1798–805.PubMedCrossRef Kuhlmann K, et al. Management of disappearing colorectal liver metastases. Eur J Surg Oncol. 2016;42(12):1798–805.PubMedCrossRef
74.
go back to reference Owen JW, et al. Colorectal liver metastases: disappearing lesions in the era of Eovist hepatobiliary magnetic resonance imaging. HPB. 2016;18(3):296–303.PubMedPubMedCentralCrossRef Owen JW, et al. Colorectal liver metastases: disappearing lesions in the era of Eovist hepatobiliary magnetic resonance imaging. HPB. 2016;18(3):296–303.PubMedPubMedCentralCrossRef
75.
go back to reference Knowles B, et al. Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy. HPB. 2012;14(5):298–309.PubMedPubMedCentralCrossRef Knowles B, et al. Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy. HPB. 2012;14(5):298–309.PubMedPubMedCentralCrossRef
76.
go back to reference Ferrero A, et al. Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease. J Gastrointest Surg. 2012;16(4):806–14.PubMedCrossRef Ferrero A, et al. Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease. J Gastrointest Surg. 2012;16(4):806–14.PubMedCrossRef
77.
78.
go back to reference Stang A, et al. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer. 2009;45(10):1748–56.PubMedCrossRef Stang A, et al. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer. 2009;45(10):1748–56.PubMedCrossRef
80.
go back to reference Ko S, et al. Parenchyma-sparing hepatectomy with vascular reconstruction techniques for resection of colorectal liver metastases with major vascular invasion. Ann Surg Oncol. 2016;23(4):501–7.PubMedPubMedCentralCrossRef Ko S, et al. Parenchyma-sparing hepatectomy with vascular reconstruction techniques for resection of colorectal liver metastases with major vascular invasion. Ann Surg Oncol. 2016;23(4):501–7.PubMedPubMedCentralCrossRef
81.
go back to reference Choti M and de Oliveira ML. Ablation therapy of liver tumors, in Atlas of Upper Gastrointestinal and Hepato-Pancreato-Biliary Surgery. Springer; 2016 p. 457–467. Choti M and de Oliveira ML. Ablation therapy of liver tumors, in Atlas of Upper Gastrointestinal and Hepato-Pancreato-Biliary Surgery. Springer; 2016 p. 457–467.
82.
go back to reference Catalano OA, et al. Vascular and biliary variants in the liver: implications for liver surgery. Radiographics. 2008;28(2):359–78.PubMedCrossRef Catalano OA, et al. Vascular and biliary variants in the liver: implications for liver surgery. Radiographics. 2008;28(2):359–78.PubMedCrossRef
83.
go back to reference Bahl M, et al. Liver steatosis: investigation of opposed-phase T1-weighted liver MR signal intensity loss and visceral fat measurement as biomarkers. Radiology. 2008;249(1):160–6.PubMedPubMedCentralCrossRef Bahl M, et al. Liver steatosis: investigation of opposed-phase T1-weighted liver MR signal intensity loss and visceral fat measurement as biomarkers. Radiology. 2008;249(1):160–6.PubMedPubMedCentralCrossRef
84.
go back to reference Lee SW, et al. Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index. Radiology. 2007;244(2):479–85.PubMedCrossRef Lee SW, et al. Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index. Radiology. 2007;244(2):479–85.PubMedCrossRef
85.
go back to reference Horowitz JM, et al. Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel. Abdom Radiol. 2017;1–17. Horowitz JM, et al. Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel. Abdom Radiol. 2017;1–17.
Metadata
Title
Liver Imaging for Colorectal Cancer Metastases
Authors
Daniel R. Ludwig
Aaron J. Mintz
Vanessa R. Sanders
Kathryn J. Fowler
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 6/2017
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-017-0391-4

Other articles of this Issue 6/2017

Current Colorectal Cancer Reports 6/2017 Go to the issue

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Stool- and Blood-Based Molecular Tests in Screening for Colorectal Cancer: Ready for Prime Time?

Systemic Therapies in Colorectal Cancer (RD Kim, Section Editor)

Second-Line Therapy for Advanced Colorectal Cancer: EGFR vs. Continuation of VEGF Inhibition

Nutrition and Nutritional Interventions in Colorectal Cancer (K Wu, Section Editor)

Dietary Patterns and Colorectal Cancer Risk: a Review of 17 Years of Evidence (2000–2016)

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine